Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer says wont...

    Bayer says wont tolerate unethical behaviour as France probes Monsanto file

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-18T09:00:04+05:30  |  Updated On 18 May 2019 9:00 AM IST
    Bayer says wont tolerate unethical behaviour as France probes Monsanto file

    Bayer, which acquired Monsanto in a $63 billion deal last year, faces mounting litigations over its weedkiller Roundup, a systemic, broad-spectrum glyphosate-based herbicide.


    FRANKFURT: Bayer said on Saturday it did not accept "unethical behaviour" following a French investigation into a suspected file assembled by the German company's seed making unit Monsanto to influence various personalities in France.


    The French prosecutor said on Friday it had opened the probe after a complaint was filed by the daily newspaper Le Monde.


    According to the newspaper and other French media, Monsanto built up a file of some 200 names that includes journalists and lawmakers in the hope of influencing their positions on pesticides.


    Read Also: Bayer can absorb Roundup costs of 5 billion euros, but not 20 billion – Moody’s


    The file, Le Monde reported, dates from 2016 and was leaked by U.S public relations and marketing agency FleishmanHillard.


    In an emailed statement, Bayer declined to comment on the investigation, saying it did not know which documents the allegations referred to.


    "We stand for openness and fair treatment of all interest groups. We do not accept any unethical behaviour in our company," it said. "That applies obviously for the data privacy regulations in the respective countries as well."


    FleishmanHillard said on Friday it would investigate the allegations in Le Monde. The company will "examine the questions raised by certain media outlets about the lists of stakeholders that included publicly available information," it said in a statement.


    Read Also: Price pressure in China; Bayer looking into established drugs strategy


    Bayer, which acquired Monsanto in a $63 billion deal last year, faces mounting litigations over its weedkiller Roundup, a systemic, broad-spectrum glyphosate-based herbicide.


    A U.S. jury in August 2018 found the company liable because Monsanto had not warned users of alleged cancer risks linked to Roundup.


    Bayer suffered a similar defeat over the weedkiller last month, while more than 13,000 plaintiffs are claiming damages. The company said last month it intended to defend itself in all lawsuits.


    Read Also: Bayer posts 45 percent gain in quarterly earnings

    BayercancerFleishman HillardFrankfurtFrench investigationglyphosateinvestigationLe MondeMonsantoplaintiffstreatmentunethical behaviourweedkiller
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok